Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
19 studies found for:    weill AND does not carry | Open Studies
Show Display Options
Rank Status Study
1 Recruiting FemVue and Tubal Patency
Condition: Tubal Patency
Intervention: Device: FemVue device
2 Recruiting Effects of Electronic Cigarettes on Lung Biology
Conditions: Lung Disease;   Lung Disorder
Interventions: Other: Group A;   Other: Group B;   Other: Group C;   Other: Group D;   Other: Group E
3 Not yet recruiting Administration of AdVEGF-All6A+ to Myocardium of Individuals With Diffuse CAD Via Minimally Invasive Surgery
Condition: Coronary Artery Disease
Interventions: Biological: AdVEGF-All6A+;   Biological: AdNull
4 Recruiting Body Composition and White Adipose Tissue Inflammation
Conditions: Breast Cancer;   Prostate Cancer;   Body Composition;   White Adipose Tissue Inflammation
Interventions: Device: DEXA Scan;   Behavioral: Godin Leisure Time Exercise Questionnaire (GLTEQ)
5 Recruiting Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Conditions: Lymphoma;   Neurotoxicity;   Therapy-related Toxicity
Interventions: Biological: rituximab;   Drug: bendamustine hydrochloride;   Drug: bortezomib;   Drug: lenalidomide
6 Recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma
Conditions: Classical Hodgkin Lymphoma;   Stage IIB Hodgkin Lymphoma;   Stage IIIB Hodgkin Lymphoma;   Stage IVA Hodgkin Lymphoma;   Stage IVB Hodgkin Lymphoma
Interventions: Biological: Bleomycin Sulfate;   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Vincristine Sulfate
7 Recruiting PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
Condition: Colorectal Cancer
Interventions: Drug: FOLFOX (chemotherapy);   Other: 5 FUCMT (chemoradiation);   Procedure: surgery;   Procedure: magnetic resonance imaging or endorectal ultrasound
8 Recruiting S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
Condition: Breast Cancer
Interventions: Drug: anastrozole;   Drug: everolimus;   Drug: exemestane;   Drug: goserelin acetate;   Drug: letrozole;   Drug: leuprolide acetate;   Drug: tamoxifen citrate;   Other: placebo
9 Recruiting Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Capecitabine;   Drug: Carboplatin;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis
10 Recruiting Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Conditions: Ductal Breast Carcinoma In Situ;   Estrogen Receptor and/or Progesterone Receptor Positive;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Multicentric Breast Carcinoma;   Multifocal Breast Carcinoma;   Synchronous Bilateral Breast Carcinoma
Interventions: Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate
11 Recruiting Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Conditions: Micropapillary Serous Carcinoma;   Ovarian Serous Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Tamoxifen Citrate;   Drug: Topotecan Hydrochloride;   Drug: Trametinib
12 Recruiting Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
Condition: Unresectable Hepatocellular Carcinoma
Intervention: Device: TheraSphere
13 Recruiting Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral CDAi in Patients With MDS
Conditions: Myelodysplastic Syndrome;   MDS
Interventions: Drug: ASTX727 Dose Escalation;   Drug: ASTX727 Dose Confirmation
14 Recruiting A Gene Therapy Study for Hemophilia B
Condition: Hemophilia B
Intervention: Genetic: SPK-9001
15 Recruiting Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Crizotinib;   Other: Laboratory Biomarker Analysis;   Other: Placebo
16 Recruiting S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
Condition: Bladder Cancer
Interventions: Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Methotrexate;   Drug: Vinblastine;   Drug: Doxorubicin;   Drug: Filgrastim
17 Recruiting Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Conditions: Large Cell Lung Carcinoma;   Lung Adenocarcinoma;   Stage IB Non-Small Cell Lung Carcinoma;   Stage IB Squamous Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIA Squamous Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIB Squamous Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Squamous Cell Lung Carcinoma
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
18 Recruiting Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
19 Recruiting Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: 99mTc-MIP-1404 Injection

Study has passed its completion date and status has not been verified in more than two years.